Evan Ballard
Clinical Researcher in Translational Psychiatry
Data updated
Research Footprint
Evan Ballard appears in 11 tracked papers (2015–2024), most studied alongside Ketamine and Placebo, across Depressive Disorders, Major Depressive Disorder (MDD) and Suicidality.
Most-cited paper: The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis (672 citations).
Frequent co-authors: Carlos Zarate, Mark John Niciu and Lawrence Park.
Publication Landscape
How the 11 papers Blossom tracks for Evan Ballard line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Evan Ballard's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 11 of 11 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Evan Ballard publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Evan Ballard publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Evan Ballard is a clinical researcher specialising in translational psychiatry with a research focus on rapid-acting antidepressants, principally ketamine, and their effects in major depressive disorder and bipolar disorder. His work spans clinical trials, phenomenological measurement of suicidal ideation, and mechanistic studies investigating sleep-related arousal and electrophysiological correlates of antidepressant response. Ballard has contributed to studies examining antisuicidal responses to ketamine and how these responses relate to sleep continuity, as well as methodological work on assessing suicidal ideation in trials of fast-acting treatments.
His publications and trial involvement reflect an emphasis on linking clinical outcomes (suicidality, fatigue, treatment-resistant depression) to objective measures including sleep architecture and electrophysiology, and on comparing effects in depressed versus healthy participants. Through this combination of clinical trial design, symptom measurement, and neurophysiological assessment, Ballard's contributions aid in understanding mechanisms of rapid antidepressant action and in refining biomarkers and outcome measures relevant to suicidality and sleep disturbances in mood disorders.
Key Impact
Noted for clinical and translational research on ketamine and rapid-acting antidepressant effects, particularly relating to suicidality, sleep/arousal, and electrophysiological biomarkers in mood disorders.
Collaboration Network
26 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Evan Ballard's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Evan Ballard is associated with.
West Virginia University
academicA public research university in Morgantown, West Virginia, with a comprehensive health sciences center including the WVU School of Medicine. The university conducts biomedical and clinical research addressing Appalachian health disparities, including studies on substance use disorders, addiction medicine, and novel psychiatric treatments relevant to the region's ongoing opioid crisis.
View stakeholder →National Institute of Mental Health (NIMH)
governmentU.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
View stakeholder →